Intranasal immunization as a preventive measure against SARS-CoV-2
DOI:
https://doi.org/10.5377/alerta.v6i2.16398Abstract
Dear Editor,
It is known that the development of intramuscular RNA vaccination has been an effective preventive measure against SARSCoV-2 infection by producing humoral and cellular immune responses that prevent viremia and systemic manifestations caused by COVID-19. However, Tiboni et al. report that the intramuscular route does not provide complete protection against viral replication due to the absence of activation of the mucosal immunity of the upper airways, preserving the risk of transmission.
Intranasal vaccination is a novel immunization approach that uses the respiratory lining as an entry point for developing antibodies. Intranasal immunization is a promising option to combat COVID-19 since by using the same route of infection as the virus, it sterilizes the respiratory tract and prevents transmission of the virus; moreover, its administration is easy and convenient for people with trypanophobia.
Downloads
172
PDF (English) (Español (España)) 47
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Maricarmen Ortiz Serrano, Efrain Eleazar Sanabria Martinez, Adriana Denisse Torres Diaz
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Privacy statement:
Alerta articles are published under license Creative Commons 4.0 CC BY: https://creativecommons.org/licenses/by/4.0/
Authorship rights
Revista Alerta gives the authors exclusive control of their work and the right to be acknowledged and cited.